10x Genomics (TXG) Misses Q1 EPS by 9c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
10x Genomics Reports First Quarter 2020 Financial Results
May 11, 2020 4:04 PM EDTPLEASANTON, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the quarter ended March 31, 2020.
Recent Highlights
Revenue of $71.9 million for the first quarter, representing a 34% increase over the corresponding period of 2019 Announced a broad range of new products and new capabilities at the Advances in Genome Biology and Technology (AGBT) Meeting in February Began shipping and completed initial placements of the Chromium Connect instrumentWe... More
